Skip to main
SYRE

SYRE Stock Forecast & Price Target

SYRE Analyst Ratings

Based on 12 analyst ratings
Strong Buy
Strong Buy 58%
Buy 42%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Spyre Therapeutics is in a strong financial position with net assets of $251 million and a strong cash position of $225 million, giving them the necessary resources to continue their research and development efforts. Overall, Spyre Therapeutics presents a promising outlook for investors with their innovative approach to IBD and other inflammatory conditions, potential for growth in multiple indications, and strong financial standing.

Bears say

Spyre Therapeutics is facing potential challenges in developing commercially viable combination regimens due to the complexities of co-formulation and potential limitations with dosing frequencies. Additionally, updates from competitors in the space could impact shares positively or negatively, and the company may need to raise additional funds to support pipeline advancement, which could have a financial impact.

SYRE has been analyzed by 12 analysts, with a consensus rating of Strong Buy. 58% of analysts recommend a Strong Buy, 42% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Spyre Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Spyre Therapeutics Inc (SYRE) Forecast

Analysts have given SYRE a Strong Buy based on their latest research and market trends.

According to 12 analysts, SYRE has a Strong Buy consensus rating as of Jun 26, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $94.17, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $94.17, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Spyre Therapeutics Inc (SYRE)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.